Intel Corporation (NASDAQ: INTC) closed Monday at $89.51, nearly flat on the day, but the stock remains 5.8% below its recent $95 public offering price. The gap represents a paper shortfall of approximately $1.16 billion for base offering buyers, underscoring the market's cautious reception of the company's capital raise.
The offering, which closed last week, involved the issuance of 210.5 million shares, equivalent to 4.2% of Intel's June share count. If underwriters exercise their full option, the dilution could reach 4.8%. The company raised about $19.7 billion in net proceeds, earmarked for general corporate purposes, including capital expenditures and working capital.
Monday's trading session saw Intel's shares fluctuate between $88.97 and $91.85, with volume of 64.99 million shares—35% below the three-month average. The subdued activity suggests that investors are still digesting the implications of the offering and the company's ongoing turnaround efforts.
The stock's recent performance has been uneven. After a 4.4% gain on Thursday, shares fell 2.9% on Friday, leaving Monday's flat close to preserve those losses. The $95 offering price now serves as a visible resistance level, with the stock trading below it since the offering's completion.
Intel's Q2 results paint a mixed picture. Revenue surged 25% to $16.13 billion, and GAAP gross margin improved to 40.4% from 27.5% a year earlier. Operating income reached $1.80 billion. However, the company's Foundry segment continues to be a drag, posting a $2.09 billion operating loss on $5.77 billion in revenue, translating to a negative 36.2% operating margin.
In contrast, Intel Products delivered $4.82 billion in segment-level operating income, with strong margins in Client and Physical AI (26.4%) and Data Center and AI (39.5%). The stark divergence underscores the challenges Intel faces as it invests heavily in its foundry business.
CFO David Zinsner has offered some optimism, noting that 14A defect density is "tracking better than the target curve" and that external customer engagement has increased. However, the timeline remains long, with 14A risk production targeted for late 2027 and volume production in 2028. Defect density improvements do not necessarily translate into commercial yield, a key metric for foundry customers.
Analyst targets reflect the uncertainty surrounding Intel's prospects. The compiled range spans from a low of $75 to a high of $200, with an average of $114.88. Intel's current price sits much closer to the low end, indicating that the market remains skeptical about the company's ability to execute on its foundry strategy.
Looking ahead, there is no earnings catalyst on the immediate horizon. Investors will likely test whether the $89 to $95 range becomes support or overhead supply. Any firm external commitment to Intel's 14A process would carry more weight than another update on defect density.
The offering has resolved Intel's financing needs, but the discount to the offering price poses a harder question: Can Intel earn an adequate return on the new capital? The answer will determine whether the stock can reclaim its offering price and move higher.
